Equities researchers at Zacks Research upped their Q2 2025 earnings estimates for CRISPR Therapeutics in a report issued on ...

ZUG, Switzerland and BOSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

BofA analyst Alec Stranahan raised the firm’s price target on Crispr Therapeutics (CRSP) to $86 from $85 and keeps a Buy rating on the shares. With sufficient cash to support “years of ...

Susquehanna Fundamental Investments LLC bought a new position in CRISPR Therapeutics during the fourth quarter valued at $3,636,000. Virtus ETF Advisers LLC grew its holdings in CRISPR ...

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Investors with a lot of money to spend have taken a bearish stance on CRISPR Therapeutics CRSP. And retail traders should know. We noticed this today when the trades showed up on publicly ...

CRISPR is a technology that can be used to edit genes and, as such, will likely change the world. The essence of CRISPR is simple: it’s a way of finding a specific bit of DNA inside a cell.

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...